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Foreword
The field of neurodevelopmental disorders is an exciting one in clinical practice. People 
with intellectual disability are more likely to have associated neurodevelopmental disorders 
such as autism and attention hyperactivity disorder (ADHD). The current practice of 
diagnosis and management of ADHD in people with intellectual disability is based 
on findings from assessment and treatments in the general population. People with 
intellectual disability often have additional comorbid disorders that may conceal or 
exacerbate the signs of ADHD and, for this reason, treatments applicable in the general 
population may not always be appropriate in treating a person with intellectual disability.
To fill this gap in knowledge and practice, this College Report on ADHD in adults with 
intellectual disability is very welcome and timely when so much more is understood 
about ADHD in general. The challenge for clinicians in supporting people with intellectual 
disability and ADHD is to deliver the best care based on good evidence on the 
effectiveness of assessment processes and treatments. This report brings together 
the current evidence as applied in people with intellectual disabilities and it benefits 
from the expertise and knowledge of clinicians, built over years of experience working 
with people with intellectual disabilities. The evidence base will grow from more original 
research on ADHD in intellectual disability to understand how the disorder manifests 
in people with intellectual disability. The report will prove to be a valuable resource to 
clinicians and services in applying evidence to support and treat ADHD in people with 
intellectual disability.
Ken Courtenay
Chair, Faculty of Psychiatry of Intellectual Disability
Royal College of Psychiatrists UK
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Scope of the report
Psychiatrists working with people with intellectual disabilities (ID) require knowledge 
and skills in assessing and managing neurodevelopmental disorders such as attention 
deficit hyperactive disorder (ADHD) and autism spectrum disorder (ASD). The presence 
of one or more neurodevelopmental disorder in people with ID can lead to a complex 
presentation of behavioural and/or mental symptoms and diagnostic and management 
challenges. ADHD in people with ID is often misdiagnosed, under-recognised and 
inadequately managed, despite ADHD-specific treatment strategies that can be highly 
effective. There is limited good quality research in ADHD specific to people with ID 
compared with that for ADHD in the general adult population. With the growing evidence 
base on ADHD in ID, there is an increased awareness of diagnosis and treatment of 
ADHD in ID but an absence of specific guidance on the disorder.
This report aims to provide an up-to-date review of the current evidence base, clarify 
the diagnostic process and summarise the management of ADHD in the ID population. 
It aims to guide psychiatrists working with people with ID to identify and treat comorbid 
ADHD. The report discusses factors that need to be considered and the value of 
screening and diagnosing ADHD alongside the pitfalls of not recognising it. It then goes 
further and extrapolates from the evidence available in people with ADHD without an ID. 
Both pharmacological and non-pharmacological management strategies are described. 
As the evidence for pharmacological interventions is limited, case vignettes have 
been used to highlight good practice. Due to the limited evidence available, some 
recommendations are derived from expert consensus. This is a pragmatic report aiming 
to give guidance using the best available practice from research and expert opinion. 
The report recognises its limitations and acknowledges that future research might refine 
the evidence further. 
We hope this helps to support clinicians in their area of practice and, most importantly, 
confers real-life benefits to patients and their families.
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Executive summary
Intellectual disability (ID) is a lifelong condition of impaired intellectual functioning 
associated with deficits in adaptive functioning. Attention deficit hyperactivity 
disorder (ADHD) is a neurodevelopmental disorder characterised by symptoms of 
inattention, hyperactivity and impulsivity. ADHD, in common with other common 
medical and psychiatric disorders, is influenced by multiple genes, non-inherited 
factors and their interplay. The correct diagnosis of ADHD helps to utilise 
evidence-based treatments, both pharmacological and non-pharmacological, 
that can improve clinical and social outcomes for people with ID. 
Comorbid psychiatric, neuropsychiatric and neurodevelopmental disorders are 
commonly seen in people with ID and ADHD. Clinical expertise is important to 
recognise comorbid mental disorders and decide which conditions need to be 
treated first. In people with ID, especially where communication and language are 
limited, differentiating phenomenological presentations such as autism spectrum 
disorder (ASD) and ADHD can be particularly challenging. ADHD and epilepsy have 
also been reported to co-occur. Therefore, it is important that all comorbidities 
are considered when supporting people with ID and ADHD. 
Diagnosing ADHD in people with ID can be challenging. The strict application of 
diagnostic criteria, such as from the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), can limit the diagnosis as some of the criteria may not be 
applicable, especially for people with more severe levels of ID. Therefore, overall, 
clinical judgment and seeking collateral reports on the presence of inattention 
and/or hyperactivity and impulsivity symptoms is important when considering 
the diagnosis of ADHD in people with ID.
The evidence base for ADHD medications in adults with ID remains limited 
to evidence used in the treatment of ADHD in the general population being 
extrapolated to the ID population. There are two main groups of ADHD 
medications, stimulants and non-stimulants. The National Institute for Health 
and Care Excellence (NICE) guidance, published in 2018, recommends using 
either lisdexamfetamine or methylphenidate as the first-line pharmacological 
treatment for adults with ADHD. The choice of ADHD medication in adults with 
ID can be influenced by factors such as the duration of symptom control needed, 
the side effect profile and available preparations. Atomoxetine is often used in 
adults with ADHD and ID because of its longer half-life compared with stimulants 
and therefore its ease of administration.
It can be a challenge to assess cardiovascular risk and cardiac disease in people 
with ADHD and ID due to the difficulty in collecting both subjective and objective 
data. In addition, there is little to no robust evidence in the scientific literature 
to guide clinical practice. To assist clinicians in arriving at balanced judgements 
under these difficult circumstances, this report provides scientific data on ADHD 
medications, a summary of the latest guidance, some tailored additions to the 
guidance and the information an assessing cardiologist may request.
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Non-pharmacological strategies can be defined as any intervention that does 
not include the use of medications. Although non-pharmacological strategies 
lack a robust evidence base, it is best practice for care plans to include non-
pharmacological interventions using personalised approaches based on cognitive 
and behavioural principles. Psychoeducation is fundamental in helping people with 
ID, and their carers, to understand the symptoms of ADHD. Cognitive Behavioural 
Therapy (CBT) has been shown in some studies to reduce the core symptoms of 
ADHD, associated symptoms and associated functional impairments. Adaptations 
may be needed for people with ID when delivering psychological interventions. 
Sleep problems are reported in up to 50% of people with ADHD and are likely to 
be more frequent in individuals with a comorbid ID. In people with ADHD and ID, 
comorbid sleep disorders can result in significant functional impairments that 
affect mood, behaviour, health, quality of life and carer burden. 
ID and ADHD combined confer an increased risk of entering the Criminal Justice 
System. Prisoners with ID have complex needs with significant problems including 
inattention, hyperactivity, impulsivity or social communication combined with 
their cognitive impairments. Comorbidities are complex in this group and the 
overlap also extends to ASD. The presentation of ADHD in people with ID could 
increase the risk of offending behaviours, so it is important to identify ADHD 
early in those with ID and implement appropriate evidence-based treatments.
Given the challenges in diagnosis and treatment, psychiatrists and other clinicians 
working with people with ADHD and/or ID should be encouraged to access case 
discussions, peer group and reflection meetings regularly and gain skills by 
attending suitable training sessions. In addition to using available evidence as 
highlighted by the current report, there is an urgent need to improve awareness 
of the significant comorbidity of ADHD and ID along with further research to the 
person-centred outcomes of ADHD in people with ID. 
It is essential that health and social care commissioners are aware and sensitive 
to the current report and its findings. Incorporating the findings of the report could 
be part of the Commissioning for Quality and Innovation (CQUIN) contracts for 
provider organisations. Equally, thought needs to be given to creating a national 
register at a primary care level to identify those diagnosed with ADHD and ID, to 
allow for evaluation and research on outcomes going forward. This would directly 
and positively influence the current national aspirations of reducing polypharmacy, 
particularly psychotropic medication and be a step towards parity of care. 
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Objectives and methodology
Objectives
• To provide guidance to psychiatrists to improve awareness and recognition of 
ADHD in people with ID.
• To provide guidance on the diagnosis and management in line with national 
standards and contemporary practice to improve outcomes for people with ID 
and ADHD. 
• To improve care and outcomes for patients and their families.
Methodology
This report attempts to combine up-to-date published research with the everyday 
practice of experts in the field of ADHD in ID. The development of this analysis was 
carried out as follows:
• A working group of experts was created through the network of ADHD in ID 
peer group of the Neurodevelopmental Disorders Special Interest Group in 
the Royal College of Psychiatrists. The group involved clinical and academic 
psychiatrists whose primary job role is in ID services and who have expertise in 
ADHD. Advisors to support the core committee were identified from cardiology, 
forensic psychiatry and sleep medicine. A service-user and his carer were also 
involved. A preliminary meeting established the objectives and framework.
• The editors conducted a focused literature review of publications on ADHD in ID 
and a review of the best practice documents and current models of care. The 
findings were collated, areas identified, discussed and considered, regarding 
their suitability for inclusion in the College Report.
• The College Report was circulated to all working group members for comments 
and feedback. The feedback received was reviewed by the editors and 
incorporated into the report.
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Chapter 1: Introduction
1.1 Intellectual disability
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defines intellectual 
disability (ID) as a developmental disorder that affects both intellectual and adaptive 
functioning in conceptual, practical and social domains (American Psychiatric Association, 
2013). ID affects approximately 2% of the population (Maulik et al, 2011). It is classified 
into mild, moderate, severe and profound, based on life skills, the need for support and 
the results of IQ testing (American Psychiatric Association, 2013). People with ID are at 
higher risk of comorbid mental disorders and neurodevelopmental disorders compared 
to people without an ID (Cooper et al, 2007; Hughes-McCormack et al, 2017; Perera 
et al, 2019b). Such disorders can make the diagnostic process more challenging in 
people with ID. 
1.2 Attention deficit hyperactivity disorder 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder 
characterised by symptoms of inattention and/or hyperactivity and impulsivity (American 
Psychiatric Association, 2013). Signs of ADHD are evident during the developmental 
period, causing functional impairment in different domains of life. The three main criteria 
for the diagnosis of ADHD in adults are:
1 the presence of five or more symptoms from inattention and/or hyperactivity 
and impulsivity domains
2 several of these symptoms must present before the age of 12 years
3 signs of functional impairment in two or more settings.
Depending on the presence of inattentive or hyperactivity/impulsivity symptoms, ADHD 
can be further categorised into three types: combined, predominantly inattentive and 
predominantly hyperactive/impulsive types.
1.3 Why does diagnosing ADHD matter?
ADHD causes significant functional impairments varying from increased comorbid mental 
illnesses, substance misuse, accidental injury and unemployment to many other domains of 
life (Gjervan et al, 2012). A recent register-based study showed increased premature death 
in people with ADHD further increased with increasing psychiatric comorbidity (Sun et al, 
2019). In people with ID, functional impairment can also present as challenging behaviour 
(Perera, 2017; Korb, 2019). This, amongst many other restrictions, can significantly reduce 
an individual’s ability to access leisure and occupational activities. The under-recognition of 
ADHD in people with ID is also likely to contribute to the overuse of non-ADHD psychotropic 
medication in people with ID and challenging behaviour (Korb et al, 2019). Therefore, the 
diagnosis of ADHD is equally important in people with ID as much as in people without ID. 
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People with ADHD and ID have a ‘double deficit’ in cognitive functioning secondary to 
both ADHD and ID. This may also predispose them to a ‘floor effect’ and diagnostic 
overshadowing. Thus, early consideration of ADHD in this patient group, with a view to 
providing treatment and support necessary to improve outcomes, is important.
There is a strong evidence base that supports the fact that treatment of ADHD can 
significantly reduce functional impairments (Chang et al, 2019; Harpin et al, 2016). 
Al-Khudairi et al (2019) showed that people with ID and ADHD on ADHD medications are 
less likely to use antipsychotic medications compared to people with ID and ADHD not 
on ADHD treatment. Therefore, it is important that the diagnosis of ADHD is considered 
in people with ID and assessed appropriately. 
1.4 Aetiology and epidemiology of ADHD in people with ID
1.4.1 Prevalence
Determining the prevalence of ADHD in people with ID can be challenging for several 
reasons. Fundamentally, there is a lack of awareness about ADHD and the absence 
of established protocols on diagnosis in this population. Differences in methodology, 
diagnostic criteria and intellectual functioning across study samples compound the 
reliability of prevalent estimates. The current evidence suggests that individuals with ID 
are at an increased risk of ADHD compared to those without ID. Rates range from 0.4% 
(Cooper et al, 2007) to 19.6% (La Malfa et al, 2008), whereas the prevalence of ADHD 
in the general population is estimated to be approximately 2.5% (Simon et al, 2009).
1.4.2 Aetiological factors
ADHD is influenced by multiple genes, non-inherited factors and their interplay. There 
is no known single cause for ADHD. Known associations include having a biological 
relative with ADHD, copy number variants, gene variants, extreme early adversity, pre/
postnatal exposure to lead, low birth rate and prematurity (Thapar et al, 2012). Individuals 
with foetal alcohol syndrome are increasingly recognised as having a high prevalence 
of ADHD of up to 75% (Young et al, 2016). 
Certain genetic syndromes are associated with ADHD (Table 1) but most people with ID 
and ADHD do not have a specific genetic syndrome. Given the possibility of underlying 
genetic syndromes, it is worth considering genetic testing of people with ID and ADHD 
on a case-by-case basis. 
CR230: Attention deficit hyperactivity disorder in adults with intellectual disability 14
Table 1: Genetic disorders associated with ADHD
Behavioural Phenotypes Chromosome Rate of comorbidity





Klinefelter syndrome XXYY >60%
Neurofibromatosis 17q11.2, 2p22-21 >38%












William’s syndrome 7q11.2 30–60%
Table adapted from Turk, 2009 
Prevalence rates taken from Ekstein et al, 2011; Leyfer et al, 2006; Lo-Castro et al, 2011; Zelenova et al, 2018
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Chapter 2: Comorbidities in adults with ADHD 
and intellectual disability
2.1 Introduction
Comorbid psychiatric, neuropsychiatric and neurodevelopmental disorders are commonly 
seen in people with ADHD (Beiderman, 1993; Kooij et al, 2012; Reale et al, 2017) and 
in people with ID (Copper et al, 2007). The presence of ID and ADHD should therefore 
prompt an assessment to rule out other comorbid disorders. This is important as specific 
comorbid disorders have bespoke treatments. Further care and consideration should 
be given to these disorders and how treatments can influence the course of ADHD 
and its management. The task of separating mental disorders from ADHD and ID can 
be challenging. Diagnostic overshadowing can often cause under-diagnosis of various 
comorbidities. This chapter considers common comorbid psychiatric, neuropsychiatric 
and neurodevelopmental disorders in people with ADHD and ID and provides evidence 
to distinguish them from ADHD.
2.2 Bipolar affective disorder
There is an overlap between symptoms of ADHD and bipolar affective disorder (BPAD), 
that can often lead to difficulties in distinguishing one condition from another. The overlap 
of the elated mood evident in manic episodes and ADHD may lead to under-diagnosis 
of either of these conditions (Biswas and Thomas, 2018). In people with ID, it can prove 
a challenge to diagnose elated mood, as mood disorders may present as behavioural 
problems more commonly in people with severe and profound levels of ID. There 
are similarities in the presentation of manic/hypomanic episodes and ADHD such 
as symptoms of racing thoughts, emotional dysregulation, distractibility, impulsivity, 
disturbance in attention or concentration and disturbed sleep. The episodic nature of 
bipolar affective disorder helps to differentiate it from ADHD. Signs of BPAD may appear 
in late adolescence or the early twenties, compared with ADHD symptoms which are 
present from childhood, emphasising the importance of a full developmental history. 
Psychotic symptoms, e.g. grandiose delusions, if present, could help in differentiating 
BPAD from ADHD. Adults with ADHD generally have a better understanding or insight 
into their symptomatology compared to a person experiencing a manic episode.
2.3 Depressive disorder
Depressive disorder is a mental disorder with signs and symptoms of persistent low 
mood (American Psychiatric Association, 2013). There is a considerable overlap between 
symptoms of ADHD and depressive disorder. Symptoms intrinsic to ADHD, such as 
inattention, sleep disturbance, irritability and emotional dysregulation, may be present 
during a depressive episode. Low mood, thoughts of worthlessness, regression, 
self-harm, suicidal ideas, reduced appetite and sleep disturbances often have a clear 
onset in a depressive disorder. 
CR230: Attention deficit hyperactivity disorder in adults with intellectual disability 16
2.4 Anxiety disorders
Anxiety may present with a range of signs and symptoms similar to those of ADHD, for 
example, internal restlessness, racing thoughts and tachycardia. A clinician needs to 
take a thorough history in order to differentiate the two conditions. Anxiety disorders 
often have a clear onset compared to ADHD which originates in childhood. The history 
should focus on the cause of the person’s anxiety and whether ADHD is a predisposing 
factor if it is comorbid. The severity of anxiety symptoms is also important to assess. 
These will help to decide whether anxiety should be treated first or whether treatment 
of ADHD may improve a person’s anxiety symptoms.
Similarly, impulsivity related to obsessive compulsive disorder and related conditions 
may be misattributed to ADHD and vice versa. 
2.5 Emotionally unstable personality disorder 
Emotionally unstable personality disorder (EUPD) is characterised by thoughts, feelings 
and behaviours that cause distress (American Psychiatric Association, 2013). Impulsivity 
is a symptom associated with both ADHD and EUPD. In EUPD, impulsivity is primarily 
driven by interpersonal factors as compared with ADHD where deficits in attention and 
cognitive processing account for impulsivity (Matthies and Philipsen, 2014).
Emotional dysregulation is a core feature of EUPD. Emotional dysregulation has 
three important components including temper control, affective lability and emotional 
over-reactivity. Although it is not a diagnostic criterion for ADHD (American Psychiatric 
Association, 2013), it is being increasingly considered as an important symptom of adult 
ADHD (Shaw et al, 2014). The pervasive patterns of unstable relationships and knowing 
that both disorders are trait presentations, as opposed to episodic in nature, further 
adds to the diagnostic complexity (Marchant, 2013; Moukhtarian, 2018).
2.6 Autism spectrum disorder
Autism spectrum disorder (ASD) is a social communication disorder that affects how 
people relate to others and in understanding their thoughts and feelings (American 
Psychiatric Association, 2013). ASD is considered a dimensional disorder that manifests 
to varying degrees. The prevalence of ASD in ID is approximately 18% compared to 
approximately 1% in the general population (Tonnsen et al, 2016). The prevalence of 
ASD was over 75% in a cohort of adults with ID and ADHD (Al-Khudairi et al, 2019). It 
may be challenging to differentiate ADHD from ASD. When assessing people with ID, 
especially where communication and language is limited, differentiating phenomenological 
presentations can be particularly challenging. A person with ADHD may present with 
symptoms of hyperactivity such as ‘not being able to sit in one place for long’ and 
presenting as ‘always on the go’. Symptoms of hyperactivity, while not included in the 
diagnostic criteria for ASD (American Psychiatric Association, 2013), can present if 
an autistic person is not engaged in their stereotypic interest. A differentiating feature 
between the two conditions is that a person with ADHD will present with pervasive 
hyperactivity, often with difficulties in regulating attention irrespective of their preferred 
activity. A person with ASD and ID may appear transiently hyperactive due to loss of 
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structure or self-identified sensory stimulation. Hypervigilance (being always aroused) and 
hyper-focus (being able to concentrate for prolonged periods on tasks) are significant 
challenges to differentiate in people with ID, ADHD and ASD.
2.7  Epilepsy
ID with comorbid ADHD is associated with more complex epilepsy presentations 
(Holdsworth et al, 1974), a higher symptom burden (Reilly et al, 2017) and higher psychiatric 
comorbidity (Ettinger et al, 2015). Antiepileptic drugs (AEDs) are also associated in 
several ways with ADHD. Valproate use in pregnancy is associated with inattentiveness 
and hyperactivity in offspring (Auvin et al, 2018). In the past, AEDs were considered 
to increase activity levels, irritability and attentional deficits in a person with epilepsy 
but most studies suggest that AEDs have little effect on cognitive functions such as 
attention (Tan et al, 2005). 
Practical considerations 
• ADHD symptoms may complicate the diagnosis of epilepsy as they may be 
mistaken for seizures.
• Treating seizures first should be the priority. If seizures can be controlled, some 
symptoms of ADHD may improve.
• Treating ADHD in a person with ID and epilepsy may lessen stress and improve 
the person’s ability to manage his or her medication and life challenges.
• A full and thorough risk assessment of epilepsy is essential. Consider using the 
SUDEP and seizure safety checklist (Shankar et al, 2019). 
• There may be concerns about worsening of seizures when starting ADHD 
medication in a person with epilepsy. The current evidence suggests that 
although people with ADHD are more likely to suffer from seizures, the rates 
are lower in individuals taking ADHD medication. Close monitoring of seizures 
is advised but epilepsy is not a contraindication to starting ADHD medication 
(Wiggs et al, 2018).
• For further recommendations for epilepsy in ID: RCPsych College Report 
CR203 and CR206. 
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Chapter 3: Assessment of ADHD in adults with 
intellectual disability 
3.1 Introduction
Assessing ADHD in adults with ID often includes taking a history from the patient and 
a collateral history from support workers, carers or family members. Reports from 
settings where the person with ID spends a lot of time, including schools, day services 
or work, is invaluable. In addition, information from videos of the person can be helpful.
ADHD diagnostic assessment includes:
1 psychiatric assessment including a detailed developmental history 
2 an assessment of ADHD symptoms as per DSM-5 or ICD-10 criteria.
A complete psychiatric history is important to assess for comorbid psychiatric, 
neuropsychiatric and neurodevelopmental disorders. 
3.2 Assessment of ADHD symptoms as per DSM-5 criteria    
 (American Psychiatric Association, 2013)
Clinicians need to explore the history of ADHD symptoms using objective diagnostic 
criteria. This can be done using a structured diagnostic tool or a clinical history focusing 
on ADHD symptoms. There are several ADHD screening and assessment tools available, 
however, only one, to date, is specific for ADHD in people with ID and can be used across 
a range of settings. The Diagnostic Interview for ADHD in Adults with ID (DIVA-5-ID) 
(McCarthy et al, 2017) is based on the DSM-5 criteria for ADHD and provides a list of 
examples from clinical practice for both current and childhood behaviour in people with 
ID for each of the 18 symptom criteria for ADHD. There are four main diagnostic criteria 
of ADHD in adults as per DSM-5:
• the presence of five or more inattentive symptoms and/or five or more 
hyperactivity and impulsivity symptoms in adulthood, that are inconsistent with 
developmental age
• several symptoms of inattentive and/or hyperactivity/impulsivity symptoms prior 
to the age of 12 years
• symptoms to be present in two or more different settings
• functional impairment secondary to the symptoms.
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Criterion 1
The presence of five or more inattentive symptoms and/or five or more hyperactivity 
and impulsivity symptoms in adulthood which are inappropriate for developmental age.
Assessment of inattention and hyperactivity/impulsivity symptoms can be challenging 
in people with ID. ADHD symptoms may present differently in people with ID. People 
with ID are often absent from settings commonly referred to in a standard diagnostic 
criterion, e.g. the workplace. As such, we have detailed how standard DSM-5 criteria 
may present in people with ID in Table 2.
Table 2: DSM-5 criteria in an adult with ADHD and ID (McCarthy et al, 2017)
DSM-5 criteria (American Psychiatric 
Association, 2013)
How they manifest in people with ID 
(Developed from clinicians’ experience)
A1. Often fails to give close attention to 
details or makes careless mistakes in 
schoolwork, at work or with other activities
Struggles to pay attention at work, home, day 
centre, college, during occupational therapy 
(OT) activities, drawing, etc.
A2. Often has trouble holding attention on 
tasks or play activities
Difficulty sustaining attention at work, home, 
during OT activities, drawing, etc.
A3. Often does not seem to listen when 
spoken to directly
Appears not to listen to the conversation, 
asks for information again, cannot remember 
parts of the conversation
A4. Often does not follow through on 
instructions and fails to finish schoolwork, 
chores or duties in the workplace, e.g. loses 
focus, side-tracked
Starts an activity but does not complete the 
task. Needs a lot of support and prompting to 
complete tasks
A5. Often has trouble organising tasks and 
activities
This is often not relevant in the ID population 
as they are usually not given the responsibility 
of organising tasks or activities, however, 
it can be manifested in their ability to plan 
simple tasks
A6. Often avoids, dislikes or is reluctant to 
do tasks that require mental effort over a 
long period of time (such as schoolwork or 
homework)
Struggles to complete a task or activity 
that take a long period of time or involves 
concentration
A7. Often loses things necessary for tasks 
and activities, e.g. school materials, pencils, 
books, tools, wallets, keys, paperwork, 
eyeglasses, mobile telephones
Will leave belongings behind even when 
aware of what is needed for the day. Will not 
know where something is if it has not been 
put in its usual place
A8. Is often easily distracted Gets distracted by every little noise. Moves 
from one task to another quickly. Will struggle 
to get back into an activity where they were 
previously engaged 
A9. Is often forgetful in daily activities Will forget where they have put objects such 
as phone or keys. This is difficult to assess in 
a person with a more severe ID who is fully 
supported with their daily activities or may not 
be in possession of a phone or keys
H1. Often fidgets, taps hands or feet or 
squirms in seat
Often cannot be still; always moving around
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Table 2: DSM-5 criteria in an adult with ADHD and ID (McCarthy et al, 2017)
DSM-5 criteria (American Psychiatric 
Association, 2013)
How they manifest in people with ID 
(Developed from clinicians’ experience)
H2. Often leaves seat in situations when 
remaining seated is expected
Often moves around, finds it hard to sit in one 
place for long durations. Finds it hard to sit 
and have their meals or stay seated on the 
lavatory 
H3. Often runs about or climbs in situations 
where it is not appropriate (adolescents or 
adults may be limited to feeling restless)
Moving around most of the time, internal 
restlessness can lead to agitated appearance. 
Runs/moves around in the waiting room of an 
outpatient clinic
H4. Often unable to play or take part quietly in 
leisure activities 
Speaks loudly, finds it hard to do activities 
quietly (for people with verbal communication)
H5. Is often ‘on the go’ acting as if ‘driven by 
a motor’
Excessive energy, often moving around, 
not able to sit in one place for long, likes to 
be outdoors most of the time engaging in 
activities
H6. Often talks excessively Talks a lot without taking turns (for people 
with verbal communication)
H7. Often blurts out answers before a 
question has been completed
Will blurt out answer to any question asked 
(for people with verbal communication)
H8. Often has trouble waiting his/her turn Becomes agitated or aggressive when asked 
to wait for any length of time. Not able to 
queue for activities, finds it hard to wait if their 
needs are not met immediately 
H9. Often interrupts or intrudes on others May not have a sense of personal space, 
interrupts other people’s conversations
Criterion 2
Several symptoms of inattentive and/or hyperactivity/impulsivity symptoms prior to the 
age of 12 years.
The current consensus is for three or more ADHD symptoms to be present before the age 
of 12 years (McCarthy et al, 2017). Trying to establish whether symptoms were present 
before the age of 12 years, especially in older people with ID, can be challenging. People 
with ID often have memory difficulties and may not be able to recall details from their 
childhood and this is compounded if relatives are not available to provide information 
to meet this criterion. It is therefore recommended that more weight is given to clinical 
opinion and that a pragmatic approach is taken when applying this criterion in cases 
where a collateral history is not available.
Criterion 3
Symptoms to be present in two or more different settings.
The presence of symptoms in two or more settings such as home, school, day 
service or work is important to assess the pervasiveness of symptoms. However, it is 
acknowledged that people with ID often lead lives which are restricted in nature and are 
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under-represented in many areas of public life, e.g. education, work or social settings. 
As such, the careful consideration of the individual’s personal context is advised when 
assessing ADHD in people with ID. 
Criterion 4
Functional impairment secondary to symptoms.
ADHD can restrict a person’s life as they cannot engage in social activities because 
of their behaviour. Functional impairment secondary to ADHD can be seen in different 
domains of life that include activities of daily living; personal life/social life; work; school; 
or attendance at a day service. ADHD symptoms may limit the ability of a person with 
ID to achieve their potential, by causing significant functional impairment, as it may often 
present as challenging behaviour (Korb et al, 2019). 
This criterion therefore requires further consideration when assessing a person with ID 
since it could be explained by the ID alone or another comorbidity such as anxiety. In 
such circumstances, it may be useful to seek the perspective of professionals involved 
with the person and who are experienced in supporting people with ID. They may be 
able to elucidate whether the severity of functional impairment is more pronounced in 
the individual being assessed compared to others on their case-load. 
3.3 Limits of DSM-5 criteria
Applying DSM-5 criteria in people with ID can be limited, especially in people with severe 
ID and with limited communication skills. A2, A8, H2 and H5 are commonly seen among 
people with ID and ADHD (Perera et al, 2019a). People with ID may be supported by 
carers in activities of daily living to varying degrees. This may limit the relevance of A5, 
A6, A7, A9 domains. People with limited communication skills may not meet A3, H6, 
H7 as these criteria are based on the person’s ability to communicate verbally. 
Strict application of the requirement to have five or more DSM-5 criteria may limit the 
diagnostic process. In such situations, the overall clinical picture and clinician’s opinion 
is considered to have more validity than the strict application of DSM-5 criteria when 
diagnosing ADHD in people with ID (Perera et al, 2019a).
3.4 Overcoming challenges
When assessing symptoms in a person with ID, a clinical judgement needs to be made 
on whether the person’s level of inattention, hyperactivity or impulsivity correlates with 
what is expected at the person’s level of developmental age. Even though this can be 
challenging, a careful history from different sources can be helpful. For example, school 
reports and information from a day centre, college, school or from care home staff who 
have experience of supporting people with similar levels of intellectual abilities may be 
helpful. Often a person with ADHD and ID is well known for being hyperactive or for 
being more distractible or needing more support to stay focused on a task compared 
to their peers with a similar level of ID.
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Chapter 4: Pharmacological management of 
ADHD in people with intellectual disabilities
4.1 Medication in ADHD and intellectual disability
The literature on ADHD medications in adults with ID remains limited with evidence in 
the general population extrapolated to the ID population. Furthermore, much of the 
research has focused on children (Aman et al, 1993; Agarwal et al, 2001; Aman et al, 
2003; Fernandez-Jaen et al, 2010; Aman et al, 2014) with no studies in adults. A recent 
systematic review by Tarrent et al (2018) on the effectiveness of methylphenidate in 
the management of ADHD in children with ID revealed 13 RCTs, one of which used 
a parallel design and the rest were crossover trials. On average, 40–50% responded 
to methylphenidate in the ID group compared to a response rate of 70–80% reported 
among the non-ID children (Courtenay and Elsner, 2016). The reasons for a lower 
response are not clear.
A Cochrane Review by Thomson et al (2009) on the use of amphetamines in ADHD 
in ID found one eligible study with a follow-up period of one week. The drawbacks 
include a small sample size (n = 15) and a short follow-up period. Despite this, the study 
highlighted some promising results with the type and rate of adverse effects among 
children with ID being similar to those in children without an ID (average 12–24%). 
Studies report various adverse effects with ADHD medications in people with ID 
(Molina-Ruiz et al, 2017) that include: sleep difficulties; poor appetite with weight loss; 
irritability; social withdrawal; and increased motor activities including tics (Tarrant et al, 
2018). Furthermore, pre-existing movement disorders may be exacerbated by ADHD 
medication, although a Cochrane Review by Osland et al (2018) found that stimulants 
do not cause a worsening in tics in most people with tic disorders.
Previous concerns regarding the use of methylphenidate in people with ASD has not 
been substantiated in recent studies that have shown positive effects of methylphenidate 
on some core symptoms of ASD. Therefore, ASD could not be considered as a 
contraindication to prescribing methylphenidate. Its epileptogenic effect is not clear 
therefore a pragmatic approach to prescribing on a case-by-case basis should be 
adopted (Tarrent et al, 2018). A review by Miller et al (2020) highlights the benefits in 
the cognitive and behavioural domains for ADHD medications in people with ID and 
suggests that higher doses may be needed. 
4.2 Guidelines on the management of ADHD
The key national and international guidelines on the pharmacological treatment of ADHD 
in the general population who do not have ID include: NICE Guidelines on Attention 
Deficit Hyperactivity Disorder: Diagnosis and Management (NG87) (National Institute 
for Health and Care Excellence 2018); Updated European Consensus Statement on 
Diagnosis and Management of Adult ADHD (Kooij et al, 2019); and the 
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British Association for Psychopharmacology Guidelines on Pharmacological Management 
of ADHD (Bolea-Alamañac et al, 2014). The guidelines were used in the preparation of 
this report. 
4.3 Pre-treatment assessment
Before prescribing medication to treat ADHD, the clinician should conduct a thorough 
assessment of the person.
• assess for underlying cardiac diseases including a history of congenital cardiac 
diseases, current cardiac symptoms such as shortness of breath, chest pain 
and a family history of sudden death in a first-degree relative aged less than 40 
years that may suggest cardiac disease.
Please refer to section 4.9 on ‘ADHD and cardiac disease’ for advice about treatment 
when there are concerns about cardiac disease **
• conduct a physical examination to include measurement of weight, blood 
pressure and heart rate. People with ID and untreated ADHD may not cooperate 
with such examinations and therefore adopting a pragmatic approach to 
decisions on treatment that may benefit the person is recommended. National 
Institute for Clinical Excellence (NICE) guidelines recommend a cardiovascular 
examination including auscultation. An electrocardiogram (ECG) is not needed 
before starting ADHD medications unless specific concerns have arisen from 
the physical history and examination.
4.4 Medication
There are two main groups of ADHD medications: stimulants and non-stimulants (Table 
3, 4 and 5). Stimulants act by blocking the reuptake of noradrenaline and dopamine. In 
addition, dexamfetamine directly stimulates dopamine release (Stahl, 2010). Atomoxetine 
more selectively targets the noradrenaline transporter but, as the noradrenaline transporter 
clears both noradrenaline and dopamine in the prefrontal cortex, atomoxetine increases 
both dopamine and noradrenaline (Bymaster et al, 2002; Kratochvil et al, 2003). Clonidine 
and guanfacine act as alpha 2 agonists on the pre-synaptic receptors, modulating the 
release of noreadrenaline and dopamine.
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Table 4: Stimulant medications for ADHD in adults with ID in the UK





5mg, 10mg, 20mg tablets 5mg–100mg Various trade names available
Methylphenidate 
modified release (MR)
Concerta XL 18mg, 27mg, 36mg, 54mg 
tablets
18mg–108mg Do not crush or chew, swallow whole
Medikinet XL 5mg, 10mg, 20mg, 30mg, 
40mg, 50mg, 60mg capsules
10mg–100mg Can be opened and mixed with food, 
have with food
Equasym XL 10mg, 20mg, 30mg capsules 10mg–100mg  
Dexamfetamine Dexamfetamine IR Dexamfetamine oral solution Oral solution 5mg/5ml 5mg– 60mg  
Dexamfetamine tablets 5mg, 10mg, 20mg 5mg–60mg
Lisdexamfetamine  Elvanse 20mg, 30mg, 40mg, 50mg, 
60mg, 70mg capsules
20mg–70mg Capsules can be opened and mixed with 
food
Information from the BNF (Joint Formulary Committee 2020)
Table 5: Non-stimulant medications for ADHD in adults with ID in the UK
Drug Preparation Trade name Formulation Dose range Other information
Atomoxetine Atomoxetine capsule 10mg, 18mg, 25mg, 40mg, 60mg, 
80mg, 100mg
40mg–120mg Can be given once or 
twice a day
Atomoxetine liquid Oral solution 4mg/1ml 40mg–120mg
Clonidine Clonidine tablet  25 micrograms (mcg), 100mcg 50mcg-1.2g (Maximum dose based 
on the indication for hypertension)
Clonidine oral solution  Oral solution 50mcg/5ml  
Guanfacine Tablet Intuniv 1mg, 2mg, 3mg, 4mg 1mg–7mg  
Information from the BNF (Joint Formulary Committee 2020)
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4.5 Medication choice for adults with ID
NICE guidelines (2018) recommend using either methylphenidate or lisdexamfetamine 
as the first-line pharmacological treatment for adults with ADHD.
• Consider switching to lisdexamfetamine for adults who have had a six-week trial 
of methylphenidate at an adequate dose but have not derived enough benefit in 
reduced ADHD symptoms and associated impairment.
• Consider dexamfetamine for adults whose ADHD symptoms are responding to 
lisdexamfetamine but who cannot tolerate the longer effect profile.
• Offer atomoxetine to adults if they cannot tolerate lisdexamfetamine or 
methylphenidate or their symptoms have not responded to two separate 
six-week trials of lisdexamfetamine and methylphenidate, having considered 
alternative preparations at adequate doses.
The choice of ADHD medication can be influenced by factors such as the duration 
of symptom control needed, side-effect profile, existing comorbidity and available 
preparations. Al-Khudairi et al (2019) showed that atomoxetine is often used in adults 
with ADHD and ID because of its longer half-life compared with stimulants and therefore 
its ease of administration.
4.6 Dose titration in adults with ID
Titrating the dose of medication helps to achieve the most effective dose with the 
minimal adverse effects.
• ADHD symptoms and functional impairments should be recorded at baseline 
and at each dose change during the dose titration period
• Start with a lower dose and titrate slowly
• Increase the dose to higher doses before ruling it out as not being effective
• Titrate the dose against symptoms and adverse effects in line with the British 
National Formulary (Joint Formulary Committee, 2019) until dose optimisation 
is achieved with reduced symptoms, positive behaviour changes and 
improvements in functional impairment with tolerable adverse effects
• Ensure that dose titration is slower and monitoring more frequent if any of the 
following are present in people with ADHD:
 − other neurodevelopmental disorders such as ASD or tic disorders
 − mental illness such as anxiety disorders, obsessive-compulsive disorder, 
schizophrenia, bipolar affective disorder, depression, personality disorder, 
eating disorder, post-traumatic stress disorder or substance misuse
 − physical health conditions, for example, cardiac disease, epilepsy or acquired 
brain injury.
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4.7 Practical considerations when prescribing ADHD medication 
 in people with intellectual disability
The following factors should be considered when prescribing in clinical practice:
• Functional impairment – does it present as challenging behaviour throughout 
the day, needing longer duration of symptom control?
• Convenience and adherence – can the person take medication as prescribed, 
especially if it needs to be taken more than once a day? What extra support is 
available to the person to take medications as prescribed?
• What facilities are available in which to store and administer controlled 
medications at home, day centre or college?
• Pharmacokinetic and pharmacodynamic profiles – does the person metabolise 
medication slower or faster than expected?
• Not responding to one stimulant medication does not mean that the person 
may not respond to another stimulant medication from the same group.
• When prescribing stimulants for ADHD, be aware that effect size, duration of 
effect and adverse effects vary from person to person.
• Consider combining in the drug regimen immediate and modified-release 
preparations of stimulants to optimise effect, for example, a modified-release 
preparation of methylphenidate in the morning and an immediate-release 
preparation of methylphenidate at another time of the day to extend the duration 
of effect.
• Prescribers should be familiar with the requirements of controlled drug 
legislation governing the prescription and supply of stimulants. (See NICE’s 
guideline on controlled drugs.)
4.8 Caution
Consider treating a comorbid anxiety disorder (if relevant) prior to starting ADHD 
medication in people with ID and ADHD because there is a risk of increased anxiety 
and worsening of behaviour. Treat anxiety first or use medications/strategies to reduce 
anxiety when starting ADHD medications. If there is worsening of anxiety and behaviour, 
stop ADHD medications and restart when the person’s level of anxiety has been treated.
4.9 Combining ADHD medications
There is no published literature on combining ADHD medications but using a combination 
of ADHD medications is seen in clinical practice when one ADHD medication does not 
fully control symptoms of ADHD. Advice from a specialist in ADHD in ID can be sought 
in such instances.
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4.10 ADHD medication and the cardiovascular system
NICE 2018 recommendations on the assessment, management and monitoring of 
cardiac disease and cardiovascular risk in people with ADHD also applies to people with 
ID. However, given that people with both ADHD and ID present specific challenges, we 
have tailored our advice accordingly. In this section pragmatic advice is provided based 
on experience, available evidence and published guidance to help clinicians exercise 
their clinical judgement on a case-by-case basis and to escalate, where appropriate, 
in what can be challenging circumstances largely unsupported by scientific evidence 
or published guidance.
The adverse cardiac effects of ADHD medications, such as hypertension and tachycardia, 
result from their adrenergic and dopaminergic activity. QTc prolongation also occurs 
through unknown mechanisms. Because data on cardiovascular safety in adults with 
ADHD and ID is absent, these recommendations are extrapolated from studies in healthy 
people and younger people with ADHD but without ID.
Reports of sudden death in adults treated for ADHD have raised concerns about an 
increased risk of sudden cardiac death but observational studies have not consistently 
shown this to be the case (Fay et al, 2019).
Before starting ADHD treatment, it is important to exercise caution in people who are 
at increased risk of decompensation caused by increases in heart rate, blood pressure 
and QTc interval that may occur. These include people with known or suspected heart 
failure, valve disease, arrhythmia, coronary artery disease, hypertension and complex 
congenital heart disease. Therefore, before starting treatment, all patients should have a 
stratified cardiovascular assessment to explore for such conditions that should include:
• a cardiovascular history (from person or carer): 
personal history of cardiac symptoms, drug history, family history of cardiac 
disease and sudden death
• a cardiovascular examination: 
signs of heart failure or murmurs
• basic cardiovascular investigations: 
height, weight, blood pressure and heart rate.
 
*A pragmatic approach is needed when a person with ID and ADHD needs treatment; 
a cardiovascular examination may not be possible due to their behaviour. Inability to 
perform a cardiovascular examination should not prevent them receiving ADHD treatment 
in the absence of evidence of a possible cardiovascular condition.
4.10.1 Blood pressure
Normal blood pressure in people with ADHD who are not on treatment should be in 
the range 100–120/60–70mmHg, the same as in healthy adults. ADHD drug treatment 
increases the average blood pressure by 3–8mmHg (systolic) and 2–14mmHg (diastolic) 
(Fay et al, 2019). These changes are small, for example the average blood pressure 
would need to rise consistently by 20mmHg (systolic) or 10mmHg (diastolic) for ten 
years to increase the incidence of cardiovascular death from 1% to 2% per decade 
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(Prospective studies collaboration, 2002). For this reason, NICE (2019) do not recommend 
diagnosing and treating hypertension until the average home blood pressure readings 
are above 135/85mmHg.
People with ADHD and ID are unlikely to experience significant increases in blood 
pressure or cardiovascular risk due to ADHD medications that would justify withholding 
treatment. Indeed, guanfacine can cause hypotension. Where clinic blood pressure 
measurement is not possible, basic measures such as reassurance, de-escalation, 
watchful waiting and home blood pressure monitoring are reasonable first steps. In 
home blood pressure monitoring, blood pressure is recorded twice in the morning and 
twice in the evening, one minute apart, for four to seven consecutive days. Values from 
day one are discarded and the remaining values are averaged. This is useful in people 
with ADHD and ID because it can be performed at home, at rest, by carers and away 
from the clinic.
Blood pressure should ideally be measured at baseline before drug treatment, before 
and after dose changes and at six-monthly intervals. Clinic readings consistently in the 
following ranges should trigger the appropriate actions:
Table 6: Actions to take depending on blood pressure (BP) values
Value Action
Systolic below 140mmHg or diastolic below 
90mmHg
Continue ADHD medications and up-titrate if 
required
Systolic above 140mmHg or diastolic above 
90mmHg
• Continue ADHD medications at the current 
dose
• Perform home BP monitoring and re-review
• Refer to cardiology if home BP readings 
remain above 135/85mmHg
Systolic above 180mmHg or diastolic above 
120mmHg
• Reduce or hold dose of ADHD medications
• Perform a cardiac history, examination, 
fundoscopy, urine dipstick, blood test 
(HbA1c, U+Es, lipids) and urine sample 
(ACR), where feasible
• Perform home BP monitoring. Refer to 
cardiology if home BP readings remain 
above 135/85mmHg
• Arrange for a GP review within seven days
• If evidence of acute end-organ dysfunction 
e.g. chest pain, new confusion, heart 
failure, proteinuria, haematuria or retinal 
damage, or it is difficult to exclude, then 
arrange for same day medical assessment. 
At a minimum, seek telephone advice, e.g. 
medical registrar on call or ambulatory care 
unit
Orthostatic hypotension due to fainting using 
guanfacine
Down titrate dose or change to alternative
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4.10.2 Heart rate
The normal heart rate is 60–100bpm in sinus rhythm. On initiating of ADHD drug 
treatment, the heart rate increases by 3–10bpm on average (Fay et al, 2019). This is a 
small rise not likely to be associated with adverse events or to justify withholding ADHD 
treatment. The risks due to sinus tachycardia in patients with ADHD, where alternative 
causes have been excluded, are extremely low. As with blood pressure, the heart rate 
should ideally be measured before and after changes in dose, and every six months, 
unless there are other indications.
ECG examination is not necessary in the absence of other specific clinical indications or 
if any of the ‘high-risk’ features listed below apply. It is recognised that taking objective 
measurements in this population can be challenging. The heart rate may be recorded 
more easily by pulse oximetry, smartphone devices, smart watches or at home, perhaps 
in combination with home blood pressure monitoring. Heart rates consistently in the 
following ranges should trigger the following appropriate actions:
Table 7: Actions to take depending on heart rate (HR) values
Value Action
60–100bpm Continue ADHD medication and up-titrate if required
100–120bpm • Continue ADHD medication at the current dose
• Look for causes including agitation, pain, concomitant 
medications, dehydration, infection, anaemia and hyperthyroidism 
• If there are concerns about more worrying causes such as sepsis, 
pulmonary embolism, cardiac ischaemia or acute heart failure, 




• Reduce or hold the dose of ADHD medication
• Consider and exclude alternative causes of sinus tachycardia 
listed above
• Perform an ECG, arrange a routine 24-hour HR monitor and refer 
to cardiology
• Discuss with ambulatory care or arrange same day hospital 
assessment
4.10.3 QTc interval
The QTc interval is the time between ventricular depolarisation and repolarisation. People 
with ADHD but not using drug therapy to treat this disorder have QTc intervals similar to 
healthy populations: average 420ms, upper limit of normal 440ms for men and 470ms 
for women, 99th centile 470ms for men and 480ms for women. The limited evidence 
suggests that cardiac risk increases exponentially above normal limits and stronger 
evidence links QTc values over 500ms to a clearly increased risk of arrhythmia (Jenkins 
et al, 2016). The QTc changes that occur when starting ADHD therapy are modest, 
ranging from minor decreases in QTc, to increases of 7ms or less (Fay et al, 2019). As a 
result, an ECG is not required before starting treatment unless there are other indications 
or any of the ‘high-risk’ features below apply. The challenges of recording an ECG in 
the setting of ADHD and ID are recognised and therefore using simple smartphone 
CR230: Attention deficit hyperactivity disorder in adults with intellectual disability 30
devices may be useful in overcoming such difficulties (Parks et al, 2017). When an ECG 
is performed, consistent QTc measurements in the following ranges should trigger the 
following appropriate actions:
Table 8: Actions to take depending on QTc values
QTc Value Action
Under 470ms (men) or 480ms 
(women)
Continue ADHD medication and up-titrate if required
Between these values and 500ms • Continue ADHD medication at the current dose
• Review drug history for other QTc-prolonging 
medications
• Assess and correct electrolyte abnormalities (Mg2+, 
Ca2+, K+)
• Perform annual ECG monitoring
• Refer to cardiology
Above 500ms • As above but reduce or hold the dose of ADHD 
medication
• Discuss with ambulatory care or arrange same day 
medical assessment
4.10.4 Cardiovascular risk
As for the general population, cardiovascular risk should be assessed, using the QRISK3 
score, at least every five years (qrisk.org/three). ‘Severe mental illness’ and ‘use of 
atypical antipsychotics’ were recently added to this score as they are associated with 
incremental increases in cardiovascular risk (Hippisley-Cox et al, 2017). Although every 
effort should be made to complete the score comprehensively, it is accepted that some 
criteria are challenging to fulfil in the mental health setting and in people with ID. An 
estimation of cardiovascular risk can be provided despite incomplete information. The 
following score should be accompanied by the following appropriate actions.
Table 9: Actions to take depending on QRISK3 score
QRISK3 score Action
<10% • Offer lifestyle advice including smoking cessation, weight loss (if 
overweight), alcohol reduction, dietary modification and regular physical 
activity
• Request that the GP optimises the management of cardiovascular risk 
factors including atrial fibrillation, chronic kidney disease, diabetes 
mellitus, dyslipidaemia, hypertension, physical inactivity and obesity
>10% As for <10%, but also request that, after the GP has excluded 
hypercholesterolaemia, familial dyslipidaemia and secondary causes of 
hyperlipidaemia, atorvastatin 20mg should be offered for the primary 
prevention of cardiovascular disease, unless contraindicated
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4.10.5 Cardiology referral
A cardiology opinion is warranted if any of the following ‘high-risk’ features are present:
• symptoms such as cardiac syncope, angina, breathlessness, ankle swelling or 
rapid and regular palpitations that start and stop suddenly
• known cardiac disease, hypertension, aortic dilatation or previous cardiac surgery
• a family history of sudden death in a first-degree relative
• a cardiac murmur on examination
• resting tachycardia above 120bpm
• QTc previously >470ms for men and 480ms for women.
Cardiology referrals should include details of the cardiac history, examination and 
investigations to date, blood pressure, heart rate and ECG findings. If deemed appropriate, 
it is also reasonable to request further investigations whilst awaiting a cardiology review 
such as an echocardiogram, e.g. suspected structural or congenital heart disease or 
24-hour cardiac monitor, e.g. tachycardia or suspected arrhythmia. If, following referral 
there is agreement between cardiology and psychiatry that ADHD treatment is safe, 
then people with ADHD and cardiac disease require slower dosing and more frequent 
monitoring. Importantly, the following cardiac diagnoses are not contraindications to 
ADHD therapy:
• mild and asymptomatic cardiac valvular stenosis or regurgitation
• asymptomatic mitral valve prolapse
• asymptomatic valve replacement or repair
• successfully repaired atrial or ventricular septal defect
• unrepaired but asymptomatic patent foramen ovale, atrial septal defect or ventricular 
septal defect.
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Chapter 5: Non-pharmacological management 
of ADHD in intellectual disability
5.1 Introduction
Non-pharmacological strategies can be broadly defined as any interventions that do not 
include the use of medications. This is an umbrella term which covers a wide range of 
activities. Currently, there are limited evidence-based non-pharmacological treatments for 
ADHD in general. The existing evidence is considered to be of low quality with imprecise 
results and multiple biases. The evidence base for non-pharmacological management 
of ADHD in people with ID is further limited (Knouse et al, 2008; Safren, 2006)
Despite the absence of evidence, ADHD requires a comprehensive, collaborative and 
multimodal treatment approach tailored to meet the unique needs of the person with ID 
and ADHD chosen from a range of non-pharmacological strategies. These strategies 
can be considered as follows:
• supporting an individual to manage the core symptoms of ADHD
• supporting the associated symptoms of ADHD, such as mood fluctuations, 
anger, emotional dysregulation, anxiety and mental illness
• reducing functional impairment, such as challenging behaviour.
Despite the paucity of evidence for non-pharmacological interventions in people with ID 
and ADHD, evidence extrapolated from studies undertaken in the general population 
and the strength of underlying theoretical principles may be helpful when supporting 
people with ADHD and ID.
Non-pharmacological interventions using personalised approaches based on cognitive 
and behavioural principles are recommended. The choice of intervention depends on 
factors such as the severity of ID, severity and nature of challenging behaviour, risks, 
motivation of the individual to engage in interventions and the availability of resources:
• psychoeducation to person with ID and/or carers
• cognitive behavioural therapy (CBT)
• organisational skills/school or workplace targeted interventions
• exercise/outdoor activities. 
5.2 Psychoeducation to person with ID and/or carers
Psychoeducation can be delivered on an individual basis and/or in a group. It can 
help people with ID and their carers to understand the symptoms of ADHD and how 
it is related to behaviours and different functional impairments. It also supports the 
psychological formulation of a person’s behavioural difficulties and mental health issues 
which can contribute valuable information to the positive behaviour support plans (PBS).
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Psychoeducation helps to reduce isolation and stigma by sharing experiences and 
knowledge with others. It is an opportunity to involve family members, close friends or 
caregivers in a person’s care.
The key concepts of psychoeducation in ADHD were outlined by Van Lammeren and 
Bruggeman (2011) as the following:
• recognition of the symptoms attributed to ADHD for each person 
• recognition of the positive aspects of ADHD for each person
• becoming aware of the functional disabilities due to ADHD
• the consequences of ADHD on different areas of life, e.g. work, social life, 
relationships, parenting
• learning how to find reliable information on ADHD
• learning to think in a constructive way about the problems related to ADHD.
 
5.3 Cognitive behavioural therapy
Cognitive behavioural therapy (CBT) has been shown in some studies to reduce the core 
symptoms of ADHD, associated symptoms such as emotion dysregulation, anxiety and 
depression, and functional impairments across different areas of daily living in adults. 
Certain adaptations may be needed for people with ID when delivering CBT depending 
on the person’s intellectual functioning (Vereenooghea and Langdon, 2013). Young 
and Bramham (2012) suggest therapists should rely more on behavioural techniques 
when delivering CBT to individuals who have both ADHD and ID and to be mindful of 
an individual’s difficulties with impulsivity if implementing a reward-based behavioural 
programme.
5.4 Organisational skills/school or workplace targeted    
 interventions
The following strategies can be implemented with carers and other support networks 
depending on the severity of the ID, the degree of functional impairment and the settings 
where ADHD symptoms can cause problems.
Box 1: Examples of different strategies (Young and Bramham, 2012) 
Reduce auditory distractions by supporting the person with ID and ADHD in a quieter place 
using low level music, noise cancelling headphones, earplugs if the person tolerates them
Reduce visual distraction by appropriate positioning in the room
Use bright colours or cue cards to attract attention to the task
Use rewards, such as tea breaks or short walks
Introduce a competitive element
Set achievable goals
Break up activities into smaller manageable tasks/goals
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5.5 Outdoor activities
Even though there is no strong evidence to support exercise, regular exercise is beneficial 
for people with ADHD. In addition to physical health benefits, it may reduce behavioural 
challenges associated with ADHD if the person has adequate space to remain active 
(Den Heijer et al, 2017). This is likely to be equally applicable to those with ID and ADHD. 
Therefore, people with ADHD and ID should have access to regular outdoor activities. 
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Chapter 6: Case vignettes
6.1 Introduction
The following case vignettes illustrate the various challenges that clinicians face when 
assessing and managing ADHD in people with ID. 
Case vignette 1 – Missed diagnosis
Sarah is a 21-year-old woman with a mild ID. She presented with thoughts of self-harm 
when distressed, getting into arguments/fights, being impulsive and not getting on with 
her family. Previous diagnoses include drug-induced psychosis, antisocial personality 
disorder and emotionally unstable personality disorder. She was unable to keep a job 
despite having the ability. She was diagnosed with ADHD and was started on a stimulant 
medication. There was a marked improvement in her symptoms that had been attributed 
to personality disorder in the past. Her aggression reduced significantly and she was 
able to take up employment in a supermarket.
Case vignette 2 – Challenging behaviour
George is a 19-year-old man with severe ID, ASD and ‘challenging behaviour’. He was 
known to Child and Adolescent Mental Health Services (CAMHS) and treated with low 
dose risperidone. His aggression escalated resulting in him being detained in hospital 
under the Mental Health Act. During his long admission to hospital he spent most of 
his days running around the vast grounds. On discharge to an urban environment, he 
damaged property, ran into the road and was aggressive. He commenced a short-acting 
stimulant which possibly made his behaviour worse. Atomoxetine was introduced 
following which he was able to access the community and engage in meaningful 
activities. In addition, the damage to property and aggression reduced, leading to less 
need for a required medication. Attempts to withdraw risperidone were not successful.
Case Vignette 3 – Non-responder
John is a 36-year-old man diagnosed with severe ID, ASD and ADHD. He presents 
with aggression, hyperactivity, restlessness, self-injurious behaviour and poor sleep 
patterns. He was given a trial of different stimulants and non-stimulant medications 
without any clear benefits.
Case Vignette 4 – Side effects
Nadia is a 19-year-old woman with moderate ID, autism and challenging behaviour. She 
was ‘always on the go’ and found it hard to sit in one place. Due to the nature of her 
behavioural difficulties, along with hyperactivity, she was accompanied by support staff 
when in the community. A diagnosis of ADHD was made and she started atomoxetine. 
Within a day of starting ADHD medication, she became extremely agitated and needed to 
be restrained several times a day. This was a clear worsening of her existing challenging 
behaviour. The non-stimulant medication was stopped and within days the aggression 
and agitation subsided but she continued to present with challenging behaviour. 
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Case vignette 5 – Genetic syndrome – Smith-Magenis Syndrome
Adam is a 19-year-old man with a diagnosis of Smith-Magenis syndrome, severe ID, 
ASD and a long history of challenging behaviour. He has struggled with his sleep 
all his life. He was ‘always on the go’, often labile in mood and exhibited physical 
and verbal aggression. He was prescribed antipsychotic medication and anti-anxiety 
medication with mild improvements. He continued to present with increasing behavioural 
difficulties as he got older and it was difficult to implement behavioural and psychological 
strategies. Due to the higher prevalence of ADHD in Smith-Magenis Syndrome, ADHD 
was considered and diagnosed. ADHD medication was started with a clear improvement 
in his hyperactivity and agitation within a few weeks. Carers were able to implement 
positive behaviour support plans with the improvement in his behaviour which further 
enhanced his quality of life. His sleep pattern improved significantly. 
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Chapter 7: Special groups
7.1 Introduction
There are certain groups of patients who require specific consideration when treating ADHD, including individuals with sleep disorders and offenders. 
7.2 Sleep disorders in adults with ADHD and ID
Sleep problems are reported in up to 50% of people with ADHD (Wajszilber et al, 2018) and are likely to be more frequent in individuals with a comorbid 
ID. Despite this, primary sleep disorders (Table 10) are often not assessed and therefore untreated. In people with ADHD and ID, comorbid sleep 
disorders can result in significant functional impairments that affect mood, behaviour, health, quality of life and carer burden.
Given that both ADHD and primary sleep disorders commonly co-exist and have a negative interactive effect (Table 10), it is important to conduct 
a baseline sleep evaluation during the initial assessment of ADHD in an individual with ID, as well as regular screening for sleep problems as part of 
ongoing ADHD management. This is of particular importance given that untreated sleep disorders are likely to reduce the efficacy of ADHD interventions 
(Stein et al, 2012).
Table 10: Common primary sleep disorders in ADHD and ID




• Pauses in nocturnal breathing
• Excessive daytime sleepiness
• Repeated nocturnal hypoxia 
increases the symptoms of 
ADHD
• Optimise weight management




• The individual may report uncomfortable sensations 
in the legs which they have to move in order to 
attain relief
• This will be most noticeable in the evening and at rest
• In individuals with communication difficulties, 
increased restlessness/agitation in the evening may 
be observed
• Insomnia may ensue from uncomfortable leg 
sensations and the need to move around
• Increased daytime fatigue
• RLS may be present in up to 
44% of individuals with ADHD
• Dopamine dysregulation and 
iron deficiency link RLS and 
ADHD
• Sleep disruption from RLS 
worsens ADHD
• RLS symptoms e.g. 
restlessness may mimic ADHD
• Iron supplementation in individuals with a 
ferritin < 75mcg/l
• Review potentially causative medications, 
e.g. SSRIs, SNRIs especially mirtazapine, 
ß-blockers, antihistamines, antiemetics, e.g. 
metoclopramide
• Reduce caffeine intake and nicotine
• Refer to a sleep disorder centre for 
assessment/management
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Table 10: Common primary sleep disorders in ADHD and ID




• The person regularly goes to sleep and wakes up >2 
hours later than is considered normal
• Enforcing ‘regular’ sleep/wake times results in 
insomnia and/or excessive daytime sleepiness
• When left to sleep/wake via the individual’s own 
rhythms there are no sleep-related difficulties
• DSPD is very common in 
ADHD (up to 70%)
• Individuals with ADHD have 
a myriad of changes in the 
biological clock, e.g. changes 
in the pineal gland and ‘clock’ 
genes
• There are also behavioural 
associations, e.g. impulsivity 
at night impedes settling down 
to sleep, leading to bedtime 
resistance and delays sleep 
onset
• Optimise control of ADHD
• Refer to a sleep disorder centre for 
assessment/management
Insomnia • Difficulty falling asleep or staying asleep despite 
adequate sleep opportunity
• Increased daytime dysfunction, e.g. irritability, low 
mood, anergia
• Insomnia is very common in 
ADHD (up to 66%)
• Unhealthy sleep practices, 
poor routines and bedtime 
resistance are more common 
in ADHD
• NICE (2015) and the British Association of 
Psychopharmacology (Wilson et al, 2019) 
recommend use of melatonin in adults with ID
• Gunning and Espie recommend:
1. Optimise sleep hygiene
2. Optimise sleep/wake schedule. This is 
best initiated by setting a fixed rising 
time that is maintained 7 days a week. 
Napping should be discouraged
3. Stimulus control, i.e. only use the 
bedroom for sleep, sex and getting 
dressed
4. Varying structured daytime activity
5. Refer to sleep disorder centre for 
assessment/management
 
In addition to an awareness of primary sleep disorders in people with 
ADHD and ID, it is important to consider the effect of ADHD medications 
on sleep. Stimulants can exacerbate sleep problems and therefore timing 
of medication administration and the preparation used must be carefully 
considered to avoid worsening or causing sleep problems in this population. 
CR230: Attention deficit hyperactivity disorder in adults with intellectual disability 39
7.3 Offenders with ADHD 
ADHD is a risk factor for entering the Criminal Justice System (CJS). In the UK, it is 
estimated that, in detention settings, about 25% of prisoners have ADHD (Young et al, 
2015). In addition, people with ID are overrepresented in prisons, with prevalence rates 
of 7% for those with an IQ less than 70 and nearer to 23% for those with borderline 
intellectual functioning (Jones and Talbot, 2010). However, little is known about how ADHD 
presents among offenders with ID in terms of their risk of entering the CJS. Prisoners 
with ID have complex needs with significant problems including inattention, hyperactivity, 
impulsivity or social communication combined with their cognitive impairments, thus 
increasing their risk of entering forensic settings (Chaplin et al, 2017).
The limited evidence available reflects high comorbidity between ID and ADHD for those in 
contact with the CJS. In a study of 240 male prisoners screened for neurodevelopmental 
disorders, 18 (7.5%) were identified using the Learning Disability Screening Questionnaire 
(LDSQ) as likely to have ID (Chaplin et al, 2017). Prisoners who screened positive on 
the LDSQ were highly likely to also screen positive for ADHD at a rate of 67%. This rate 
compares to studies in non-offender populations, such as La Malfa et al (2008), using 
the Conner’s Adult ADHD rating scale in 46 adults with ID, which found a prevalence 
of ‘ADHD-positive’ of 19.6%.
Studies across clinical settings have explored the interaction between ADHD and ID 
with equivocal findings. In a longitudinal study of former Norwegian child psychiatric 
in-patients (n = 541) who were matched to the National Register of Criminality, conduct 
disorder and hyperkinetic conduct disorder (RR = 2.7, 95% CI = 1.6-4.4) were reported 
as significant predictors of future criminality whereas ID was a protector against future 
offending (Modre et al, 2011). In a UK study of 477 adults with ID in specialist forensic 
ID services (non-ADHD group n= 73 v ADHD group n= 404) those in the ADHD group 
showed higher rates of physical aggression, substance use and histories of aggression, 
sexual offences, property offences, birth problems and abuse in childhood. It was also 
noted that impulsivity related to ADHD was not a universal explanation for offending as 
this may have been a trait in the non-ADHD sample (Lindsay et al, 2013).
7.3.1 Implications for practice
Screening for both ID and ADHD across the Criminal Justice System has been highlighted 
in key national documents such as the Bradley report (2009) and should be introduced 
as routine practice across the System. However, these recommendations have been 
in place for several years, with limited uptake within forensic settings.
The presentation of ADHD in people with ID may be an indicator of an increased risk for 
offending type behaviours. It is therefore important to identify ADHD early in those with 
ID and implement appropriate evidence-based treatments. An ADHD diagnosis is also 
relevant within rehabilitative programmes because, if the diagnosis is not recognised, 
it is likely that an individual’s ability to benefit from treatment will be negatively affected. 
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Chapter 8: Personal story 
An interview with a person with ID and ADHD and their mother.
What was your life like before starting medication for ADHD?
I was anxious. My anxiety level was very high. I was struggling with sleep. I was 
angry with the whole world. I used to break things, hit walls. Once I damaged a 
door, I could see right through it. I used to bang my head on the doors. I could not 
go on the bus or be in places where there were too many people. This stopped 
me going to shops and other places. Someone always had to be with me. I found 
it hard to manage my anger and temper. I used to pick my skin a lot when I was 
restless and angry 
What was your son like before starting medication for ADHD and what difference has 
medication made?
He used to follow me everywhere. I had to talk to him for days if we were planning 
to go out on a bus or train. He would get very anxious, very irritable and agitated 
leading to behavioural problems. He would push people out of his way when he 
was outside. He did not like people blocking his way. He would shout at them. 
He was angry with everyone and he was aggressive.
Since he was started on treatment there has been a clear improvement. His mood 
is a lot more stable. He is calm. He is relaxed. He can engage in a conversation. 
His sleep is so much better. This is somebody who always struggled with his sleep 
all his life. He used to wake up in the middle of the night and disturb everyone else 
in the house. He was always moving around and could not sit in one place but 
now he can sit and enjoy various things. He now has got two jobs. He works in 
a bakery and in a cleaning job. He takes a bus to get to work which he could not 
do in the past. He does not get angry as much as he used to. Since he started 
his job, he is very proud of himself. He bought a TV, shelves and blinds for his 
bedroom. His bedroom looks a lot nicer compared to how it was, as in the past 
he used to damage and destroy some of his personal belongings.
He can now go to the shops on his own and buy things for himself which he could 
never do in the past. He is more independent and I do not need to support him 
as much I used to. I am so pleased with the progress he has made.
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Appendix
How to write a stimulant (controlled drug) prescription
All stimulants come under controlled drug regulations in the UK. There are specific 
requirements that the clinician must adhere to when writing a prescription. The dose 
and the total number of tablets or capsules needs to be written in numbers and letters.
Box 2: Examples of stimulant prescriptions
Prescription for lisdexamfetamine 50mg OD for 28 days:
Lisdexamfetamine 50mg capsules. Take one capsule at 8am. 
Supply 28 (twenty-eight) capsules of lisdexamfetamine 50mg (fifty) capsules
Prescription for methylphenidate immediate release 15mg three times a day for 28 days:
Methylphenidate immediate release 5mg tablets. Take one tablet three times a day
Methylphenidate immediate release 10mg tablets. Take one tablet three times a day
Supply 84 (eighty-four) tablets of methylphenidate 5mg (five) tablets
Supply 84 (eighty-four) tablets of methylphenidate 10mg (ten) tablets
Prescription for Concerta XL 63mg OD for 28 days:
Concerta XL 36mg tablets. Take one tablet at 8am. 
Concerta XL 27mg tablets. Take one tablet at 8am
Supply 28 (twenty-eight) tablets of Concerta XL 36mg (thirty-six) tablets
Supply 28 (twenty-eight) tablets of Concerta XL 27mg (twenty-seven) tablets
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